Indole derivative compounds acting as ferroptosis inhibitors have been reported in a Mitoimmune Therapeutics Inc. patent as potentially useful for the treatment of neurodegeneration, diabetes, stroke, myocardial infarction, liver, lung diseases, eye, renal disorders, among others.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have patented N-acylhydrazone compounds acting as sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers which are described as being potentially useful for the treatment of pain.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly patented aromatic acetylene derivatives acting as UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors and reported to be useful for the treatment of gram-negative bacterial infections.
Sisaf Ltd. has entered into a collaboration with the University of Leipzig to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.
An ongoing outbreak of mpox, a viral disease of zoonotic origin, was confirmed in May 2022 and has affected many countries worldwide. The spread of the virus is due to human-to-human transmission, but it remains unclear whether the responsible mpox strain is adapting to a new host.
The pathogenesis of eosinophilic gastroenteritis (EGE), a chronic inflammatory disease characterized by eosinophil infiltration in the gastrointestinal tract, is still not well understood.
Thymmune Therapeutics Inc. has secured US$7 million in seed financing to support its work in developing scalable thymic cell therapies to restore immune function in aging and disease.
Resistin-like molecule beta (RELMβ) is a gut-derived cytokine involved in both allergic responses and protection from pathogens, and it has been previously found to be dysregulated in mouse models of food allergy (FA). Researchers from Boston Children’s Hospital aimed assess the potential of RELMβ as a novel biomarker in children with FA.
Tyra Biosciences Inc. is expanding development of TYRA-300 into achondroplasia based on promising preclinical results from a study conducted in collaboration with the Imagine Institute. A specific mutation in fibroblast growth factor receptor 3 (FGFR3) causes over 97% of achondroplasia.
A new study found that nebulized mRNA therapy could be an effective approach to treating acute respiratory distress syndrome (ARDS), a rapidly progressing lung disease that can lead to respiratory failure and death. This work focused on two genes, nuclear factor kappaB (NF-κB) inhibitor α super-repressor (IκBα-SR) and superoxide dismutase 3 (SOD3), previously shown to reduce the severity of pneumonia when delivered prophylactically by viral vectors.
RSS
